A slightly different mode of action is employed by the anti-PD-L1/4-1BB DuoBody GEN1046, which activates T-cells and NK cells by simultaneously blocking PD-L1 on tumor tissue and triggering the co-stimulatory checkpoint 4-1BB [95]. Here, CD274 is linked to neoplasm.